EC approves subcutaneous route of administration in Sandoz biosimilar, Binocrit
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in its drug Binocrit (epoetin alfa), a prescription medicine that stimulates the bone marrow to produce red blood cells (anemia in either the nephrology or oncology setting).
“By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients” said Carol Lynch, Global Head Biopharmaceuticals, Sandoz.
The EU approval was based on data from the SENSE clinical study – an open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
The company says it is committed to increasing patient access to high-quality, life-enhancing biosimilars
About author
You might also like
U.S. appeals court dismisses case over alleged suicide link with GSK’s antidepressant
A U.S. appeals court on Wednesday tossed a $3 million verdict against GlaxoSmithKline over the suicide of an attorney who took a generic version of the company’s antidepressant Paxil (named
Aspirin may halve air pollution harms
A new study has revealed evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function. This findings were published in
GSK, PSN introduce online training for pharmacists
Multinational pharmaceutical giant, GlaxoSmithKline, (GSK) has partnered the Pharmaceutical Society of Nigeria (PSN) to introduce an innovative online training program for pharmacists in the country. The programme, tagged Scientific Course
0 Comments
No Comments Yet!
You can be first to comment this post!